Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042288 · ClinicalTrials.gov registry record · Phase 2
Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT01042288 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 70 participants.
The verdict
NCT01042288, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this multicenter, Phase II trial is to examine the role of a well-tolerated novel agent, panitumumab, in combination with a modern platinum doublet regimen using carboplatin and pemetrexed, in patients with advanced non-squamous wild type K-ras non-small-cell lung cancer (NSCLC). If this treatment proves to be well tolerated and associated with efficacy, this would provide rationale for further randomized studies.
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Panitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2010-06 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01042288
The ClinicalTrials.gov registry entry for NCT01042288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT01042288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01042288 about?
NCT01042288 is a clinical study titled "Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC". The purpose of this multicenter, Phase II trial is to examine the role of a well-tolerated novel agent, panitumumab, in combination with a modern platinum doublet regimen using carboplatin and pemetrexed, in patients with advanced non-squamous wild type K-ras non-small-cell lung cancer (NSCLC). If t...
What is the current status of trial NCT01042288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2010-06. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01042288?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Panitumumab (DRUG).
Who is sponsoring clinical trial NCT01042288?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.